Dernières nouvelles pour ProPhase Labs (NASDAQ:PRPH) Stock

ProPhase Labs

ProPhase Labs Inc is a diversified company offering various services, including diagnostic testing, genomics testing, and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers, and government organizations. The Consumer Products segment is engaged in the research, development, manufacture, distribution, marketing, and sale of OTC consumer healthcare products and dietary supplements in the United States. It also provides personal genomics products and services.

ProPhase Labs Inc

Shares of ENDRA Life Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) rose sharply in pre-market trading after the company announced it will be granted a US patent titled &#8220;<a href="https://www.benzinga.com/quote/NDRA">Radio Frequency Applicator&#8221;.</a>
ENDRA Life Sciences shares jumped 61.4% to $5.58 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul class="wp-block-list">
<li>Bolt Projects Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSLK#NASDAQ">BSLK</a>) surged 71.8% to $4.36 in pre-market trading.</li>
<li>Optical Cable Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCC#NASDAQ">OCC</a>) climbed 44.2% to $5.22 in pre-market trading after the company entered into a strategic collaboration agreement with Lightera to expand offerings for data center and enterprise.</li>
<li>IT Tech Packaging, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITP#NYSE">ITP</a>) rose 40.1% to $0.2601 in pre-market trading.</li>
<li>BioSig Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) jumped 27.3% to $14.70 in pre-market trading. BioSig and Streamex announced up to $1.1 billion in growth financing to launch gold-backed treasury strategy and RWA tokenization platform.</li>
<li>Viomi Technology Co., Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIOT#NASDAQ">VIOT</a>) gained 20.8% to $3.19 in pre-market trading after jumping 59% on Monday.</li>
<li>Globavend Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GVH#NASDAQ">GVH</a>) gained 19.6% to $0.0975 in pre-market trading after gaining 8% on Monday.</li>
<li>The Chemours Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CC#NYSE">CC</a>) gained 18.5% to $14.70 in pre-market trading.</li>
<li>Wolfspeed, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) gained 13.7% to $2.66 in pre-market trading. Wolfspeed shares jumped 96% on Monday after the company announced it appointed Gregor van Issum As CFO.</li>
<li>Vor Biopharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VOR#NASDAQ">VOR</a>) gained 12.4% to $3.00 in pre-market trading after jumping 40% on Monday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul class="wp-block-list">
<li>Blue Gold Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGL#NASDAQ">BGL</a>) dipped 15.6% to $63.00 in pre-market trading after dipping 30% on Monday.</li>
<li>ProMIS Neurosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMN#NASDAQ">PMN</a>) shares tumbled 14.3% to $0.3507 in pre-market trading after falling over 5% on Monday.</li>
<li>LogProstyle Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LGPS#NYSE">LGPS</a>) fell 14.3% to $1.45 in pre-market trading after gaining around 108% on Monday.</li>
<li>La Rosa Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRHC#NASDAQ">LRHC</a>) dipped 12.2% to $7.37 in pre-market trading after dipping 30% on Monday.</li>
<li>Helius Medical Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) fell 10.9% to $8.42 in pre-market trading. Helius Medical Technologies filed prospectus for $25 million share offering.</li>
<li>ProPhase Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) fell 10.4% to $0.3961 in pre-market trading after gaining more than 5% on Monday.</li>
<li>MediaCo Holding Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDIA#NASDAQ">MDIA</a>) declined 10.2% to $1.23 in pre-market trading after gaining 25% on Monday.</li>
<li>Pelthos Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTHS#NASDAQ">PTHS</a>) declined 8.3% to $23.79 in pre-market trading after gaining 60% on Monday.</li>
<li>SolarEdge Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) shares fell 5.1% to $25.08 in pre-market trading after declining 4% on Monday.</li>
<li>Sunrun Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) fell 4.8% to $10.58 in pre-market trading after gaining more than 5% on Monday.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46289573/trump-tariffs-sink-dow-over-400-points-investor-sentiment-declines-but-fear-greed-index-remains-in-extreme-greed-zone">Trump Tariffs Sink Dow Over 400 Points: Investor Sentiment Declines, But Fear &amp; Greed Index Remains In &#8216;Extreme Greed&#8217; Zone</a> </li>
</ul>
Photo via Shutterstock

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

BSGM

BSLK

HSDT

LGPS

LRHC

MDIA

NDRA

PRPH

PTHS

SEDG

VIOT

WOLF

Why ENDRA Life Sciences Shares Are Trading Higher By Over 61%; Here Are 20 Stocks Moving Premarket

ProPhase Labs Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>), (the "Company" or "ProPhase") a next generation biotech, genomics and consumer products company, today announced that it has received an extension of 180 calendar days (the "Extension Notice") from The Nasdaq Stock Market LLC ("Nasdaq") to regain compliance with the Nasdaq's minimum $1.00 bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on Nasdaq (the "Bid Price Requirement"), following the expiration of the initial 180 calendar days period to regain compliance on June 24, 2025. NASDAQ stated that it based its determination to grant the extension based on the Company meeting all other applicable requirements for initial listing on the Capital Market with the exception of the bid price requirement.
As previously announced, the Company received a written notification from Nasdaq dated December 26 2024, indicating that because the closing bid price of the Company's common shares for the previous 30 consecutive business days was below $1.00 per share, the Company was not in compliance with the Bid Price Requirement, and Nasdaq granted the Company a period of 180 calendar days, or until June 24, 2025, to regain compliance with the Bid Price Requirement.
As of the date hereof, the Company has not regained compliance with the Bid Price Requirement. Pursuant to the Extension Notice, the Company is eligible for an additional 180 calendar day period, or until December 22, 2025, to regain compliance with the Bid Price Requirement. To regain compliance, the Company's Class A ordinary shares must have a closing bid price of at least US$1.00 per share for a minimum of 10 consecutive business days. In the event that compliance cannot be demonstrated by December 22, 2025, the staff of Nasdaq will provide written notification that the Company's securities will be delisted.
The Company intends to monitor the closing bid price of its common shares between now and December 22, 2025, and is considering its options to regain compliance with the Bid Price Requirement. The Company believes that the Extension Notice does not affect the Company's business operations, its U.S. Securities and Exchange Commission reporting requirements, or its contractual obligations.

Government

Regulations

ProPhase Labs Receives Nasdaq Extension Until December 2025 to Regain Compliance With $1.00 Bid Price Requirement

WIIM

ProPhase Labs shares are trading higher after the company announced the completion of a key validation study evaluating the performance of the BE-Smart molecular diagnostic test compatibility with samples obtained from esophageal brush cytology.

<h3>Gainers</h3>
<ul>
<li>Acurx Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACXP#NASDAQ">ACXP</a>) stock moved upwards by 235.5% to $1.03 during Tuesday's pre-market session. The company's market cap stands at $24.1 million. </li>
<li>Salarius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) shares rose 82.37% to $1.14. The company's market cap stands at $2.4 million. </li>
<li>Verve Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>) shares moved upwards by 75.93% to $11.03. The company's market cap stands at $983.3 million. </li>
<li>Azitra (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AZTR#AMEX">AZTR</a>) stock increased by 38.35% to $0.37. The company's market cap stands at $6.1 million. </li>
<li>ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) shares moved upwards by 34.0% to $0.45. The market value of their outstanding shares is at $18.5 million. </li>
<li>Prime Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRME#NASDAQ">PRME</a>) shares increased by 16.66% to $1.75. The market value of their outstanding shares is at $229.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Adial Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) stock fell 34.8% to $0.21 during Tuesday's pre-market session. The market value of their outstanding shares is at $1.8 million. </li>
<li>Dyne Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) shares decreased by 21.86% to $10.8. The company's market cap stands at $1.2 billion. </li>
<li>Unicycive Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UNCY#NASDAQ">UNCY</a>) shares declined by 20.66% to $0.6. The market value of their outstanding shares is at $72.1 million. </li>
<li>Synaptogenix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNPX#NASDAQ">SNPX</a>) shares decreased by 14.99% to $3.63. The market value of their outstanding shares is at $5.0 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock fell 11.06% to $0.3. The market value of their outstanding shares is at $7.2 million. </li>
<li>Surgery Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGRY#NASDAQ">SGRY</a>) stock decreased by 9.8% to $20.9. The market value of their outstanding shares is at $2.6 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACXP

ADIL

AZTR

CYCC

PRME

SGRY

SLRX

SNPX

UNCY

VERV

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

BE-Smart represents a significant advance in diagnosis and management of Esophageal disease that affects an estimated 60 million people in the United States
Study shows &gt;95% success rate, validating BE-Smart for use with esophageal brush cytology.
ProPhase Labs Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>), (the "Company" or "ProPhase") a next generation biotech, genomics and consumer products company, today announced the successful completion of a key validation study evaluating the performance of the BE-Smart&#x2122; molecular diagnostic test compatibility with samples obtained from esophageal brush cytology. The study demonstrated BE-Smart&#x2122; achieved greater than a 95% technical success rate, confirming the BE-Smart's ability to reliably and accurately detect our panel of biomarkers, designed to assess progression risk in Barrett's esophagus and other distal esophageal conditions. Prophase will now move to accelerated commercialization of BE-Smart&#x2122; with expected clinical launch in the next 2-3 quarters.
BE-Smart uses a proprietary panel of biomarkers and a multi-modal analysis method which together significantly increase detection of deadly cancer cells in one of the fastest growing cancer indications, esophageal denocarcinoma cancer or "EAC". EAC has a 5-year mortality rate of over 79% and surged in annual incidence over 750% since the 1970s. BE-Smart represents a technical advance in detection and prognosis which has the potential to change cost and outcomes for the large population affected by GERD, Barrett's and EAC globally.

ProPhase Labs Validates BE-Smart Test; Study Demonstrates High Accuracy; Clinical Rollout Expected Within 2-3 Quarters

ProPhase Labs Forms Clinical Science Advisory Board To Support Clinical Adoption And Commercialization Of Breakthrough BE-Smart Molecular Test For Esophageal Disease

PRPH stock has given up its prior gain. ProPhase Labs shares were trading higher after the company reported a Q1 EPS beat.

ProPhase Labs shares are trading higher after the company reported a Q1 EPS beat.

ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.18) by 27.78 percent. This is a 59.38 percent increase over losses of $(0.32) per share from the same period last year. The company reported quarterly sales of $1.43 million which missed the analyst consensus estimate of $2.45 million by 41.59 percent. This is a 60.62 percent decrease over sales of $3.63 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

ProPhase Labs Q1 EPS $(0.13) Beats $(0.18) Estimate, Sales $1.43M Miss $2.45M Estimate

<h3>Companies Reporting Before The Bell</h3>
• DouYu Intl Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOYU#NASDAQ">DOYU</a>) is estimated to report earnings for its first quarter. 
• Freightos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGO#NASDAQ">CRGO</a>) is projected to report quarterly loss at $0.10 per share on revenue of $6.78 million. 
• Eagle Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXP#NYSE">EXP</a>) is likely to report quarterly earnings at $2.43 per share on revenue of $478.95 million. 
• Canaan (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAN#NASDAQ">CAN</a>) is likely to report quarterly loss at $0.15 per share on revenue of $89.12 million. 
• IHS Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHS#NYSE">IHS</a>) is estimated to report quarterly earnings at $0.17 per share on revenue of $421.26 million. 
• Nebius Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIS#NASDAQ">NBIS</a>) is projected to report quarterly loss at $0.44 per share on revenue of $57.73 million. 
• Vipshop Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VIPS#NYSE">VIPS</a>) is expected to report quarterly earnings at $0.66 per share on revenue of $3.62 billion. 
• GDS Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDS#NASDAQ">GDS</a>) is estimated to report quarterly loss at $0.22 per share on revenue of $374.51 million. 
• Viking Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VIK#NYSE">VIK</a>) is likely to report quarterly loss at $0.27 per share on revenue of $841.18 million. 
• H World Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTHT#NASDAQ">HTHT</a>) is projected to report quarterly earnings at $0.42 per share on revenue of $754.09 million. 
• Home Depot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>) is likely to report quarterly earnings at $3.59 per share on revenue of $39.25 billion. 
• Amer Sports (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AS#NYSE">AS</a>) is projected to report quarterly earnings at $0.16 per share on revenue of $1.39 billion. 
• Bilibili (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BILI#NASDAQ">BILI</a>) is estimated to report quarterly earnings at $0.06 per share on revenue of $947.72 million. 
• Elbit Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESLT#NASDAQ">ESLT</a>) is likely to report quarterly earnings at $2.30 per share on revenue of $1.69 billion. 
• ATRenew (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RERE#NYSE">RERE</a>) is estimated to report quarterly earnings at $0.05 per share on revenue of $636.00 million. 
• BW LPG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWLP#NYSE">BWLP</a>) is likely to report earnings for its first quarter. 
• ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) is estimated to report quarterly loss at $0.18 per share on revenue of $2.45 million. 
• Eltek (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELTK#NASDAQ">ELTK</a>) is estimated to report earnings for its first quarter. 
• NexGen Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NXE#NYSE">NXE</a>) is projected to report earnings for its first quarter. 
• ZKH Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZKH#NYSE">ZKH</a>) is expected to report earnings for its first quarter. 
• Pony AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>) is estimated to report earnings for its first quarter. 
• Arbe Robotics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBE#NASDAQ">ARBE</a>) is projected to report quarterly earnings at $0.08 per share on revenue of $100 thousand. 
<h3>Companies Reporting After The Bell</h3>
• James Hardie Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JHX#NYSE">JHX</a>) is estimated to report earnings for its fourth quarter. 
• Beeline Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLNE#NASDAQ">BLNE</a>) is expected to report earnings for its first quarter. 
• CXApp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CXAI#NASDAQ">CXAI</a>) is projected to report earnings for its first quarter. 
• Viasat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSAT#NASDAQ">VSAT</a>) is expected to report quarterly earnings at $0.17 per share on revenue of $1.14 billion. 
• Tuya (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TUYA#NYSE">TUYA</a>) is projected to report earnings for its first quarter. 
• Bioceres Crop Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOX#NASDAQ">BIOX</a>) is likely to report quarterly loss at $0.10 per share on revenue of $61.87 million. 
• FinVolution Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FINV#NYSE">FINV</a>) is estimated to report earnings for its first quarter. 
• Ellington Credit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EARN#NYSE">EARN</a>) is estimated to report earnings for its first quarter. 
• Modine Manufacturing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOD#NYSE">MOD</a>) is likely to report quarterly earnings at $0.96 per share on revenue of $633.13 million. 
• Evolv Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVLV#NASDAQ">EVLV</a>) is likely to report earnings for its first quarter. 
• Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) is expected to report quarterly earnings at $0.77 per share on revenue of $2.28 billion. 
• Keysight Techs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEYS#NYSE">KEYS</a>) is projected to report quarterly earnings at $1.65 per share on revenue of $1.28 billion. 
• Toll Brothers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOL#NYSE">TOL</a>) is estimated to report quarterly earnings at $2.88 per share on revenue of $2.51 billion. 
• ZTO Express (Cayman) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTO#NYSE">ZTO</a>) is expected to report earnings for its first quarter. 
• KNOT Offshore Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNOP#NYSE">KNOP</a>) is likely to report quarterly earnings at $0.18 per share on revenue of $79.73 million. 
• Auna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AUNA#NYSE">AUNA</a>) is projected to report quarterly earnings at $0.16 per share on revenue of $305.60 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARBE

AUNA

BILI

BIOX

BLNE

BWLP

CRGO

CXAI

DOYU

EARN

ELTK

ESLT

EVLV

FINV

HTHT

KEYS

KNOP

NBIS

Nuveen Arizona Dividend Advantage Municipal Funds 3

PANW

PONY

RERE

TUYA

VIPS

VSAT

Earnings Scheduled For May 20, 2025

ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-05-20. Here's what investors need to know before the announcement.
Analysts estimate that ProPhase Labs will report an earnings per share (EPS) of $-0.18. 
Investors in ProPhase Labs are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Overview of Past Earnings</h3>
The company's EPS missed by $0.32 in the last quarter, leading to a 0.07% drop in the share price on the following day.
Here's a look at ProPhase Labs's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.27</td>
<td>0.04</td>
<td>-0.24</td>
<td>-0.28</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.59</td>
<td>-0.35</td>
<td>-0.33</td>
<td>-0.07</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-0.0%</td>
<td>-2.0%</td>
<td>-10.0%</td>
<td>3.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1747667013_0.png" alt="eps graph" />
<h3>Performance of ProPhase Labs Shares</h3>
Shares of ProPhase Labs were trading at $0.387 as of May 16. Over the last 52-week period, shares are down 92.95%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/PRPH/earnings">To track all earnings releases for ProPhase Labs visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ProPhase Labs's Earnings Outlook

<h3>Gainers</h3>
<ul>
<li>Aptevo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) stock rose 39.2% to $1.2 during Monday's pre-market session. The market value of their outstanding shares is at $3.8 million. </li>
<li>Portage Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) shares moved upwards by 13.26% to $8.88. The company's market cap stands at $14.6 million. </li>
<li>Sunshine Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) stock moved upwards by 12.79% to $1.41. The company's market cap stands at $5.1 million. </li>
<li>Invivyd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVVD#NASDAQ">IVVD</a>) shares rose 12.6% to $0.57. The company's market cap stands at $68.8 million. </li>
<li>ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) stock increased by 11.07% to $0.32. The market value of their outstanding shares is at $9.6 million. </li>
<li>Alvotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVO#NASDAQ">ALVO</a>) shares increased by 10.97% to $9.2. The market value of their outstanding shares is at $2.7 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Vincerx Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINC#NASDAQ">VINC</a>) stock fell 48.3% to $0.14 during Monday's pre-market session. </li>
<li>Adagio Medical Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADGM#NASDAQ">ADGM</a>) shares decreased by 23.02% to $1.37. The market value of their outstanding shares is at $21.1 million. </li>
<li>China SXT Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) stock fell 17.6% to $1.78. The market value of their outstanding shares is at $24.4 million. </li>
<li>Cuprina Holdings (Cayman) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUPR#NASDAQ">CUPR</a>) shares fell 16.17% to $4.15. The market value of their outstanding shares is at $87.1 million. </li>
<li>Sensei Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNSE#NASDAQ">SNSE</a>) stock decreased by 15.79% to $0.34. The market value of their outstanding shares is at $8.5 million. </li>
<li>Redhill Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDHL#NASDAQ">RDHL</a>) stock decreased by 13.26% to $1.96. The company's market cap stands at $3.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADGM

ALVO

APVO

CUPR

IVVD

PRTG

RDHL

SBFM

SNSE

SXTC

VINC

12 Health Care Stocks Moving In Monday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) stock increased by 73.1% to $0.8 during Friday's regular session. The company's market cap stands at $9.2 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock rose 43.62% to $34.9. The market value of their outstanding shares is at $454.1 million. </li>
<li>Reshape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) stock rose 37.05% to $0.52. The company's market cap stands at $1.7 million. </li>
<li>Aldeyra Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALDX#NASDAQ">ALDX</a>) shares rose 32.04% to $1.88. The company's market cap stands at $111.6 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) stock moved upwards by 23.95% to $3.57. The market value of their outstanding shares is at $54.3 million. </li>
<li>Kairos Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#AMEX">KAPA</a>) shares moved upwards by 22.34% to $1.15. The company's market cap stands at $15.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>NeuroOne Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMTC#NASDAQ">NMTC</a>) stock declined by 44.3% to $0.48 during Friday's regular session. The market value of their outstanding shares is at $14.7 million. </li>
<li>Aptevo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) shares fell 32.16% to $1.35. The market value of their outstanding shares is at $1.9 million. </li>
<li>Lifecore Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFCR#NASDAQ">LFCR</a>) stock fell 22.62% to $5.27. The company's market cap stands at $195.1 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) stock fell 22.2% to $0.27. The company's market cap stands at $8.1 million. As per the news, the Q4 earnings report came out 4 days ago. </li>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) stock declined by 22.11% to $0.44. The market value of their outstanding shares is at $2.3 million. </li>
<li>Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) shares decreased by 20.6% to $0.26. The market value of their outstanding shares is at $66.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADAP

ALDX

KAPA

LFCR

NIVF

NMTC

RSLS

12 Health Care Stocks Moving In Friday's Intraday Session

ProPhase Labs shares are trading lower after the compant reported worse-than-expected FY24 financial results.

ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) reported FY24 losses of $(2.61) per share which missed the analyst consensus estimate of $(1.27) by 105.51 percent. This is a 411.76 percent decrease over losses of $(0.51) per share from the same period last year. The company reported quarterly sales of $6.80 million which missed the analyst consensus estimate of $13.02 million by 47.77 percent. This is a 56.29 percent increase over sales of $4.35 million the same period last year.

ProPhase Labs FY24 EPS $(2.61) Misses $(1.27) Estimate, Sales $6.80M Miss $13.02M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) is estimated to report quarterly loss at $1.36 per share on revenue of $2.69 million. 
• ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) is likely to report quarterly loss at $0.24 per share on revenue of $3.77 million. 
• Synergy CHC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNYR#NASDAQ">SNYR</a>) is estimated to report quarterly earnings at $0.10 per share on revenue of $10.55 million. 
• Westport Fuel Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WPRT#NASDAQ">WPRT</a>) is estimated to report quarterly loss at $0.28 per share on revenue of $70.35 million. 
• Loar Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOAR#NYSE">LOAR</a>) is projected to report quarterly earnings at $0.11 per share on revenue of $102.51 million. 
• Brainstorm Cell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>) is expected to report earnings for its fourth quarter. 
• Edible Garden (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDBL#NASDAQ">EDBL</a>) is estimated to report quarterly loss at $9.00 per share on revenue of $4.12 million. 
• Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) is likely to report quarterly earnings at $0.00 per share on revenue of $16.98 million. 
• Lazydays Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GORV#NASDAQ">GORV</a>) is expected to report earnings for its fourth quarter. 
• FTC Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTCI#NASDAQ">FTCI</a>) is projected to report quarterly loss at $0.84 per share on revenue of $11.61 million. 
• Sigma Lithium (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGML#NASDAQ">SGML</a>) is projected to report quarterly earnings at $0.06 per share on revenue of $77.16 million. 
• Workhorse Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKHS#NASDAQ">WKHS</a>) is expected to report quarterly loss at $4.38 per share on revenue of $3.06 million. 
• LM Funding America (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMFA#NASDAQ">LMFA</a>) is estimated to report quarterly loss at $1.67 per share on revenue of $1.50 million. 
• Data Storage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTST#NASDAQ">DTST</a>) is estimated to report quarterly earnings at $0.03 per share on revenue of $6.20 million. 
• BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) is expected to report quarterly earnings at $0.00 per share on revenue of $7.72 million. 
• IM Cannabis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMCC#NASDAQ">IMCC</a>) is estimated to report quarterly loss at $0.39 per share on revenue of $10.43 million. 
• LanzaTech Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNZA#NASDAQ">LNZA</a>) is expected to report quarterly loss at $0.14 per share on revenue of $23.55 million. 
• Palvella Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PVLA#NASDAQ">PVLA</a>) is likely to report earnings for its fourth quarter. 
• Nano X Imaging (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNOX#NASDAQ">NNOX</a>) is expected to report quarterly loss at $0.15 per share on revenue of $3.80 million. 
• Chicago Atlantic BDC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIEN#NASDAQ">LIEN</a>) is estimated to report quarterly earnings at $0.29 per share on revenue of $11.00 million. 
• BOS Better Online Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOSC#NASDAQ">BOSC</a>) is likely to report earnings for its fourth quarter. 
<h3>Companies Reporting After The Bell</h3>
• T Stamp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDAI#NASDAQ">IDAI</a>) is projected to report quarterly loss at $1.80 per share on revenue of $510 thousand. 
• Local Bounti (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOCL#NYSE">LOCL</a>) is expected to report quarterly loss at $3.89 per share on revenue of $10.95 million. 
• Vivos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VVOS#NASDAQ">VVOS</a>) is estimated to report quarterly loss at $0.43 per share on revenue of $3.89 million. 
• Siyata Mobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYTA#NASDAQ">SYTA</a>) is projected to report earnings for its fourth quarter. 
• Open Lending (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPRO#NASDAQ">LPRO</a>) is estimated to report quarterly earnings at $0.02 per share on revenue of $24.03 million. 
• Nutex Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUTX#NASDAQ">NUTX</a>) is estimated to report quarterly earnings at $0.00 per share on revenue of $81.13 million. 
• Talphera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLPH#NASDAQ">TLPH</a>) is expected to report earnings for its fourth quarter. 
• CXApp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CXAI#NASDAQ">CXAI</a>) is likely to report quarterly earnings at $0.00 per share on revenue of $2.00 million. 
• Spire Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPIR#NYSE">SPIR</a>) is projected to report earnings for its fourth quarter. 
• Gorilla Tech Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRRR#NASDAQ">GRRR</a>) is projected to report earnings for its Fiscal Year 2024. 
• Spruce Power Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPRU#NYSE">SPRU</a>) is expected to report earnings for its fourth quarter. 
• Omeros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) is estimated to report earnings for its fourth quarter. 
• Microvast Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVST#NASDAQ">MVST</a>) is estimated to report quarterly earnings at $0.00 per share on revenue of $92.50 million. 
• Gryphon Digital Mining (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRYP#NASDAQ">GRYP</a>) is estimated to report quarterly loss at $0.16 per share on revenue of $3.90 million. 
• Red Cat Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCAT#NASDAQ">RCAT</a>) is projected to report quarterly loss at $0.09 per share on revenue of $7.49 million. 
• Digi Power X (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGXX#NASDAQ">DGXX</a>) is likely to report quarterly loss at $0.12 per share on revenue of $14.30 million. 
• Rani Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RANI#NASDAQ">RANI</a>) is projected to report earnings for its fourth quarter. 
• Nortech Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSYS#NASDAQ">NSYS</a>) is likely to report earnings for its fourth quarter. 
• VolitionRX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VNRX#AMEX">VNRX</a>) is projected to report quarterly loss at $0.05 per share on revenue of $545 thousand. 
• iShares Gold Trust Shares of the iShares Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IAU#NYSE">IAU</a>) is projected to report quarterly loss at $0.02 per share on revenue of $37.70 million. 
• i-80 Gold (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IAUX#AMEX">IAUX</a>) is projected to report earnings for its fourth quarter. 
• Sidus Space (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIDU#NASDAQ">SIDU</a>) is expected to report earnings for its fourth quarter. 
• Wrap Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WRAP#NASDAQ">WRAP</a>) is likely to report earnings for its fourth quarter. 
• MDB Capital Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDBH#NASDAQ">MDBH</a>) is estimated to report earnings for its fourth quarter. 
• Duos Technologies Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOT#NASDAQ">DUOT</a>) is expected to report quarterly loss at $0.34 per share on revenue of $1.60 million. 
• Dare Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DARE#NASDAQ">DARE</a>) is likely to report quarterly loss at $0.63 per share on revenue of $1.00 million. 
• Celcuity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELC#NASDAQ">CELC</a>) is projected to report earnings for its fourth quarter. 
• CytoSorbents (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSO#NASDAQ">CTSO</a>) is likely to report quarterly loss at $0.07 per share on revenue of $9.43 million. 
• Venu Holding (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VENU#AMEX">VENU</a>) is expected to report earnings for its fourth quarter. 
• Alpha Cognition (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACOG#NASDAQ">ACOG</a>) is estimated to report earnings for its fourth quarter. 
• ESS Tech (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWH#NYSE">GWH</a>) is projected to report quarterly loss at $1.33 per share on revenue of $6.30 million. 
• Aqua Metals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQMS#NASDAQ">AQMS</a>) is estimated to report earnings for its fourth quarter. 
• Nuvve Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVVE#NASDAQ">NVVE</a>) is projected to report earnings for its fourth quarter. 
• Expion360 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XPON#NASDAQ">XPON</a>) is projected to report quarterly loss at $0.96 per share on revenue of $1.70 million. 
• CaliberCos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CWD#NASDAQ">CWD</a>) is likely to report quarterly loss at $0.04 per share on revenue of $6.69 million. 
• Precipio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPO#NASDAQ">PRPO</a>) is expected to report earnings for its fourth quarter. 
• Progress Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRGS#NASDAQ">PRGS</a>) is projected to report quarterly earnings at $1.39 per share on revenue of $234.69 million. 
• PVH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVH#NYSE">PVH</a>) is likely to report quarterly earnings at $3.24 per share on revenue of $2.34 billion. 
• Invesco National AMT-Free Municipal Bond ETFo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PZA#NYSE">PZA</a>) is projected to report quarterly earnings at $0.25 per share on revenue of $168.10 million. 
• BioHarvest Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHST#NASDAQ">BHST</a>) is likely to report earnings for its fourth quarter. 
• Babcock &amp; Wilcox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BW#NYSE">BW</a>) is projected to report quarterly loss at $0.01 per share on revenue of $212.30 million. 
• Bionano Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNGO#NASDAQ">BNGO</a>) is expected to report quarterly loss at $8.40 per share on revenue of $6.30 million. 
• Innovate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VATE#NYSE">VATE</a>) is likely to report earnings for its fourth quarter. 
• TechTarget (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTGT#NASDAQ">TTGT</a>) is expected to report quarterly earnings at $0.45 per share on revenue of $62.37 million. 
• Rekor Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REKR#NASDAQ">REKR</a>) is expected to report quarterly loss at $0.08 per share on revenue of $12.91 million. 
• Flexible Solutions Intl (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/FSI#AMEX">FSI</a>) is projected to report quarterly earnings at $0.09 per share on revenue of $10.83 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACOG

AQMS

BCLI

BHST

BLRX

BNGO

BOSC

CELC

CRIS

CTSO

DARE

DGXX

DTST

DUOT

EDBL

FTCI

GORV

GRRR

GRYP

IAUX

IDAI

IMCC

LIEN

LMFA

LNZA

LOAR

LOCL

LPRO

MDBH

MVST

NNOX

NSYS

NUTX

NVVE

OMER

PRGS

PRPO

PVLA

PowerShares Insured Municipal Bond Portfolio

RANI

RCAT

REKR

SGML

SIDU

SNYR

SPIR

Spruce Power Holding Corporation Class A Common Stock

SPRU

SYTA

TLPH

TTGT

VATE

VENU

VERO

VNRX

VVOS

WKHS

WPRT

WRAP

XPON

Earnings Scheduled For March 31, 2025

ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) will release its quarterly earnings report on Monday, 2025-03-31. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate ProPhase Labs to report an earnings per share (EPS) of $-0.24.
The market awaits ProPhase Labs's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Performance in Previous Earnings</h3>
During the last quarter, the company reported an EPS missed by $0.39, leading to a 2.42% drop in the share price on the subsequent day.
Here's a look at ProPhase Labs's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.04</td>
<td>-0.24</td>
<td>-0.28</td>
<td>-0.26</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.35</td>
<td>-0.33</td>
<td>-0.07</td>
<td>-0.51</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-2.0%</td>
<td>-10.0%</td>
<td>3.0%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1743181361_0.png" alt="eps graph" />
<h3>Performance of ProPhase Labs Shares</h3>
Shares of ProPhase Labs were trading at $0.46 as of March 27. Over the last 52-week period, shares are down 93.76%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<a href="https://www.benzinga.com/quote/PRPH/earnings">To track all earnings releases for ProPhase Labs visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

An Overview of ProPhase Labs's Earnings

<h3>Gainers</h3>
<ul>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) stock moved upwards by 22.7% to $2.7 during Wednesday's after-market session. The market value of their outstanding shares is at $31.0 million. </li>
<li>Ocean Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) stock increased by 15.41% to $0.1. The company's market cap stands at $13.5 million. </li>
<li>Acrivon Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRV#NASDAQ">ACRV</a>) shares increased by 11.09% to $2.81. The market value of their outstanding shares is at $87.5 million. </li>
<li>ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) stock increased by 10.41% to $0.53. The market value of their outstanding shares is at $16.0 million. </li>
<li>Zentalis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZNTL#NASDAQ">ZNTL</a>) shares rose 7.94% to $1.9. The company's market cap stands at $135.3 million. The company's, Q4 earnings came out today. </li>
<li>Immunome (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNM#NASDAQ">IMNM</a>) shares rose 7.19% to $7.6. The market value of their outstanding shares is at $660.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Petros Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) stock decreased by 20.8% to $0.11 during Wednesday's after-market session. The market value of their outstanding shares is at $2.7 million. </li>
<li>OSR Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSRH#NASDAQ">OSRH</a>) stock fell 12.14% to $3.33. The market value of their outstanding shares is at $64.1 million. </li>
<li>Alvotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVO#NASDAQ">ALVO</a>) stock fell 9.1% to $10.5. The company's market cap stands at $3.1 billion. As per the news, the Q4 earnings report came out today. </li>
<li>AEON Biopharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AEON#AMEX">AEON</a>) shares decreased by 8.71% to $0.64. As per the press release, Q4 earnings came out 2 days ago. </li>
<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) stock fell 8.0% to $1.9. The company's market cap stands at $2.0 million. </li>
<li>SILO Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILO#NASDAQ">SILO</a>) stock fell 5.84% to $1.28. The company's market cap stands at $5.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACRV

AEON

APDN

IMNM

OCEA

OSRH

PTPI

SILO

ZNTL

12 Health Care Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Tenon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>) stock rose 300.3% to $3.92 during Tuesday's regular session. The market value of their outstanding shares is at $12.2 million. As per the press release, Q4 earnings came out 3 days ago. </li>
<li>Predictive Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POAI#NASDAQ">POAI</a>) stock rose 72.19% to $1.92. The company's market cap stands at $13.8 million. </li>
<li>ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) stock rose 31.6% to $0.56. The market value of their outstanding shares is at $17.0 million. </li>
<li>Forte Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBRX#NASDAQ">FBRX</a>) shares increased by 25.71% to $7.95. The market value of their outstanding shares is at $50.7 million. </li>
<li>IO Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOBT#NASDAQ">IOBT</a>) stock increased by 24.61% to $1.25. The company's market cap stands at $82.1 million. </li>
<li>Zhengye Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYBT#NASDAQ">ZYBT</a>) shares rose 21.55% to $7.05. The market value of their outstanding shares is at $334.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) stock declined by 59.8% to $1.36 during Tuesday's regular session. The market value of their outstanding shares is at $2.0 million. </li>
<li>Mural Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MURA#NASDAQ">MURA</a>) shares declined by 59.27% to $1.56. The company's market cap stands at $26.8 million. </li>
<li>IMAC Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BACK#NASDAQ">BACK</a>) shares declined by 59.05% to $0.17. </li>
<li>Cormedix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) shares decreased by 33.8% to $7.13. The company's market cap stands at $432.6 million. The company's, Q4 earnings came out today. </li>
<li>Cassava Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>) stock decreased by 32.33% to $1.9. The market value of their outstanding shares is at $91.1 million. </li>
<li>Galecto (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLTO#NASDAQ">GLTO</a>) stock decreased by 23.88% to $5.1. The company's market cap stands at $6.6 million. The company's, Q4 earnings came out 4 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BACK

CNSP

CRMD

FBRX

GLTO

IOBT

MURA

POAI

SAVA

TNON

ZYBT

12 Health Care Stocks Moving In Tuesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) stock increased by 39.2% to $2.06 during Monday's pre-market session. The market value of their outstanding shares is at $1.5 million. </li>
<li>Allarity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLR#NASDAQ">ALLR</a>) shares moved upwards by 20.2% to $1.19. The market value of their outstanding shares is at $5.2 million. </li>
<li>Capstone Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPS#NASDAQ">CAPS</a>) stock rose 19.18% to $2.05. The market value of their outstanding shares is at $2.8 million. </li>
<li>Tharimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THAR#NASDAQ">THAR</a>) shares rose 17.94% to $1.7. The market value of their outstanding shares is at $3.2 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares increased by 17.7% to $69.01. The company's market cap stands at $898.0 million. </li>
<li>ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) stock rose 16.54% to $0.36. The market value of their outstanding shares is at $10.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>23andMe Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ME#NASDAQ">ME</a>) stock declined by 44.1% to $1.0 during Monday's pre-market session. The market value of their outstanding shares is at $26.8 million. </li>
<li>Unity Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UBX#NASDAQ">UBX</a>) shares decreased by 37.0% to $1.15. The market value of their outstanding shares is at $19.3 million. </li>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) shares decreased by 32.6% to $0.75. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) stock declined by 13.92% to $4.27. The market value of their outstanding shares is at $49.1 million. </li>
<li>SunLink Health Systems (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SSY#AMEX">SSY</a>) shares decreased by 12.46% to $0.95. The market value of their outstanding shares is at $6.6 million. </li>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) stock fell 10.89% to $0.38. The company's market cap stands at $1.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

ProPhase Labs

Actualités

Dernières nouvelles pour ProPhase Labs (NASDAQ:PRPH) Stock

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL